Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Circulating Sfrp2 in Iranian Polycystic Ovarian Syndrome Patients With Infertility and Recurrent Pregnancy Loss and Its Correlation With Insulin Resistance and Inflammation Publisher Pubmed



Jawad AAK1 ; Nabatchian F1 ; Moradi N2 ; Choobineh H1 ; Fadaei R3, 4 ; Afrisham R1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
  3. 3. Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
  4. 4. Department of Pharmacology, Vanderbilt University, Nashville, TN, United States

Source: Current Protein and Peptide Science Published:2025


Abstract

Introduction: Secreted Frizzled-Related Protein 2 (SFRP2) is considered to be the most potent modulator of the Wnt signaling. This pathway is involved in the pathogenesis of Polycystic Ovary Syndrome (PCOS). This research aimed to compare the levels of SFRP2 in PCOS [infertile and Recurrent Pregnancy Loss (RPL) patients] with the control group and determine the correlation of SFRP2 with inflammation and insulin resistance. Methods: This case-control study was conducted on 108 POCS patients (53 infertile patients and 55 women with RPL) and 54 healthy controls. The levels of biochemical factors along with SFRP2, adiponectin, Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), free testosterone, and insulin, high-sensitivity C-Reactive Protein (hs-CRP) were measured following the manufacturer's instructions. Results: Both infertile and RPL groups presented notably higher levels of SFRP2 (49.32 ± 17.72 ng/ml and 55.89 ± 17.36 ng/ml, respectively) compared to the control group (30.21 ± 10.12 ng/ml, P<0.001 for both groups). In PCOS patients, a positive correlation was observed between SFRP2 and body mass index (BMI) (r = 0.42, P < 0.001), insulin (r = 0.19, P = 0.04), fasting blood glucose (FBG) (r = 0.24, P = 0.01), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (r = 0.21, P = 0.03), triglyceride (r = 0.25, P = 0.009), and hs-CRP (r = 0.21, P = 0.02). Furthermore, SFRP2 increased the risk of RPL (OR [95% CI] = 1.15 [1.10 -1.20], P < 0.001) and infertility (OR [95% CI] = 1.12 [1.07 -1.17], P < 0.001) in comparison with the controls. Conclusion: Our findings suggested that SFRP2 may have a potential involvement in the development of PCOS and might be a promising target for diagnosis, but additional research is required to confirm this. © 2025 Bentham Science Publishers.